High affinity CD16v/v allogeneic NK cell therapy, AB-101, enhances antibody-mediated cytotoxicity in B-cell driven diseases.

AlloNK (AB-101) - Artiva Biotherapeutics

Rituxan (rituximab) - Roche

http://www.ncbi.nlm.nih.gov/pubmed/42475795

Amanda Conerty; Claudia Palomino La Torre; Gina Chu; Heather K Raymon; Hyo-J Kim; Ianne C Rivera; Kun-Y Teng; Lisa Guerrettaz; Mallory P Murray; Meghan Eberhardt; Paul Rogers; Sean Stromberg; You-S Kim

Jul 21, 2026